SAM
ARQT icon

Smartleaf Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Smartleaf Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.9K Hold
820
– – ﹤0.01% 1956
2026
Q1 		$17.5K Buy
820
+56
+7% +$1.43K ﹤0.01% 2032
2025
Q4 		$21.5K Buy
764
+19
+3% +$486 ﹤0.01% 1989
2025
Q3 		$13.9K Buy
745
+426
+134% +$6.72K ﹤0.01% 1972
2025
Q2 		$4.38K Buy
319
+53
+20% +$743 ﹤0.01% 2094
2025
Q1 		$4.18K Hold
266
– – ﹤0.01% 2251
2024
Q4 		$3.78K Sell
266
-161
-38% -$1.76K ﹤0.01% 2345
2024
Q3 		$4K Buy
+427
New +$4.21K ﹤0.01% 2221

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Smartleaf Asset Management's ARQT Position: Q2 2026 in Review

Smartleaf Asset Management held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 820 shares worth $21.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1956.

Smartleaf Asset Management first reported a position in ARQT in Q3 2024 and has held it in 8 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Smartleaf Asset Management held 820 shares of Arcutis Biotherapeutics worth $21.9K as of Q2 2026.
  • Smartleaf Asset Management left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q2 2026, its #1956 holding.
  • Smartleaf Asset Management first reported a position in Arcutis Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Smartleaf Asset Management's 13F filing for Q2 2026, filed 12 Aug 2026.